Valuation: AstraZeneca PLC

Market Cap 265B 238B 219B 199B 372B 25,137B 376B 2,629B 1,044B 13,176B 993B 972B 41,782B P/E 2026 *
22.3x
P/E 2027 * 19.1x
Enterprise Value 285B 256B 236B 214B 401B 27,100B 406B 2,835B 1,126B 14,205B 1,071B 1,048B 45,045B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 4.12x
Free-Float
96.62%
Yield 2026 *
1.96%
Yield 2027 * 2.08%
1 day+0.53%
1 week+2.08%
Current month+4.85%
1 month+3.07%
3 months-0.49%
6 months-7.37%
Current year-6.63%
1 week 12,520
Extreme 12520
12,980
1 month 11,716
Extreme 11716
12,980
Current year 10,524
Extreme 10524
15,732
1 year 10,524
Extreme 10524
15,732
3 years 9,461
Extreme 9461
15,732
5 years 8,090.32
Extreme 8090.32
15,732
10 years 3,996
Extreme 3996
15,732
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Chief Operating Officer 55 2015-05-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Free

See remarks

2 0.0000% -
9/14/26 Free

Chief Financial Officer

73 0.0000%
9/14/26 Buy

Chairman

2,500 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.53%+2.17%+3.79%+26.01% 265B
+1.21%+1.85%+57.81%+128.78% 1,143B
+1.41%+5.59%+45.62%+85.13% 647B
+0.59%+1.11%+26.55%+102.94% 506B
+0.16%+1.71%+52.70%+65.23% 384B
-0.08%-5.50%+62.75%+37.94% 350B
+1.35%+2.62%+31.69%+53.85% 293B
+1.26%+3.24%+54.93%+71.95% 242B
+0.77%+4.38%+35.98%+106.11% 197B
-0.96%-1.76%-22.40%-62.06% 171B
Average +0.61%+0.70%+34.94%+61.59% 419.86B
Weighted average by Cap. +0.81%+0.65%+42.42%+81.72%

Financials

2026 *2027 *
Net sales 63.32B 56.83B 52.48B 47.59B 88.94B 6,015B 90.03B 629B 250B 3,153B 238B 233B 9,998B 67.37B 60.46B 55.83B 50.63B 94.62B 6,399B 95.79B 669B 266B 3,354B 253B 247B 10,637B
Net income 11.75B 10.54B 9.74B 8.83B 16.5B 1,116B 16.7B 117B 46.35B 585B 44.1B 43.15B 1,855B 13.63B 12.24B 11.3B 10.25B 19.15B 1,295B 19.38B 135B 53.8B 679B 51.18B 50.08B 2,153B
Net Debt 20.67B 18.55B 17.13B 15.53B 29.03B 1,963B 29.39B 205B 81.56B 1,029B 77.59B 75.93B 3,263B 13.23B 11.87B 10.96B 9.94B 18.58B 1,257B 18.81B 131B 52.21B 659B 49.66B 48.6B 2,089B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-10-28 GBX 12,826.00 +0.03% 585,919
26-10-27 GBX 12,822.00 -0.25% 2,232,524
26-10-26 GBX 12,854.00 +0.23% 1,613,010
26-10-23 GBX 12,824.00 -1.20% 2,164,896
26-10-22 GBX 12,980.00 +2.90% 1,798,653
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
170.62USD
Average target price
210.22USD
Spread / Average Target
+23.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC